Current Position and Professional Functions
Dr. Shabbir Alibhai is a Professor in the Department of Medicine, the Institute of Health Policy, Management, and Evaluation, and the Institute of Medical Sciences at the University of Toronto. He is a staff physician in the Division of General Internal Medicine and Geriatrics at the University Health Network and Mount Sinai Hospital, a senior scientist at the Toronto General Research Institute and the Toronto Rehabilitation Institute, and a prior Research Scientist of the Canadian Cancer Society. His research interests are in geriatric oncology, particularly in the impact of disease and treatment on quality of life and function of patients with prostate cancer, the value of geriatric assessment in older adults with cancer, and randomized trials of exercise to improve outcomes in older adults with cancer. Since 2015, he is also the medical lead for the geriatric oncology program at the Princess Margaret Cancer Centre, Canada’s largest academic cancer centre.
Education and Training
Dr. Alibhai graduated from medical school at the University of Toronto in 1993; completed his training in both internal medicine and geriatric medicine in 1998, and went on to complete a Master's of Science in Clinical Epidemiology and Health Care Research at the University of Toronto in 2001.
Search for Shabbair Alibhai's publications in Pubmed.
Research Interests and Expertise
Dr. Alibhai's research focuses on geriatric oncology, in particular, the interaction between cancer, its treatment and the older adult. He uses a variety of research methodologies to gain insight into this issue: quality of life analyses to examine health effects of treatment; administrative databases to monitor patterns of diagnosis, referral, and therapy; decision analysis to identify optimal therapy.
His major foci relate to prostate cancer and acute myeloid leukaemia and he is currently conducting randomized trials to impact on health outcomes (informed decision making, quality of life and fatigue) in men with prostate cancer.